来自不同血管床的内皮细胞对实验性高血糖症和甲福明的异质代谢反应
C McAleese1, G Joudah2,3, I P Salt2
1School of Cardiovascular and Metabolic Sciences, University of Glasgow, Glasgow, UK.
The Journal of physiology
|February 25, 2025
概括
来自不同血管床的内皮细胞 (ECs) 显示出独特的代谢特征. 它们对高葡萄糖和甲胺的反应取决于这种基础代谢,这表明针对糖尿病并发症的向代谢疗法.
科学领域:
- 血管生物学 血管生物学
- 代谢健康 代谢健康
- 内分泌学 在内分泌学.
背景情况:
- 内皮功能障碍是糖尿病血管并发症的早期指标.
- 内皮细胞 (ECs) 具有高度的甘油性,线粒体起到信号作用.
- 不同血管床的ECs的代谢异质性及其对糖尿病并发症的影响仍然不清楚.
研究的目的:
- 研究人类大动脉,皮肤,视网膜和大脑EC中的代谢变异.
- 为了确定基底EC代谢是否影响它们对实验性高血糖 (HG) 的反应.
- 评估甲福明在独立于血糖控制的情况下保持内皮功能方面的潜力.
主要方法:
- 来自不同血管床的人类初级ECs使用海马分析仪进行分析.
- 在基底条件下,实验性高血糖 (HG) 和甲福林治疗下,代谢功能进行了比较.
- 评估了线粒体功能,呼吸道概况和甘油性功能.
主要成果:
- 在来自不同血管床的EC中观察到呼吸和糖分作用的显著差异 (例如,大动脉EC是有氧的,皮肤EC是糖分的).
- HG改变了线粒体网络区域,并影响了糖溶性功能,其影响可能取决于基底利用率.
- 甲福明影响了基底呼吸和增强了视网膜和大脑EC中的葡萄糖分解.
结论:
- 内皮细胞对HG和甲胺的反应受其内在代谢特征的影响.
- 针对EC新陈代谢提供了在糖尿病患者中保持内皮功能的潜力.
- 要了解糖尿病血管并发症并制定治疗策略,需要一种细微的方法.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
67.7K
06:35Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
Published on: April 5, 2024
849
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
152
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
152
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
